Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

NCT03079440 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT03079440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03079440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2017
Completion date
November 15, 2022
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

capecitabine, neuroendocrine carcinoma, neuroendocrine tumors, temozolomide